{
  "docId": "019de072-1a15-7369-8097-68fb5b1d5017",
  "docSlug": "de0c004f3134112f269aa7aa17f1a1f3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 39,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Slide 28 of a presentation, likely from AstraZeneca's financial reporting.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1a15-7369-8097-68fb5b1d5017/28",
  "deckHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017",
  "deckJsonHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017.json",
  "deckAnchorHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.63,
        "x": 0.35,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Opportunity for geographic expansion leveraging AstraZeneca's footprint",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a47400b7-9b4c-4c08-a71f-9470165aad87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Pro rata growth by region (US, EU, ERoW, EM) comparing FY 2020 and FY 2021",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdf19856-e4e7-4a45-abcd-87c1b6b2d30a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.36,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Rare Disease performance by product (Soliris, Ultomiris, Strensiq, Kanuma, Andexxa) for Q4 2020, Q4 2021, FY 2020, FY 2021",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1af27567-8303-4cf3-9642-6e90516ea136",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "list",
      "text": "Performance commentary for Soliris, Ultomiris, Strensiq, Kanuma, and Andexxa",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b7425b3-2352-4df9-ac19-b4b54d8406f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "FY 2021 revenues from date of acquisition closing... 2. Inclusive of total revenues previously reported by Alexion...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85903777-80e4-463a-b6db-d6e515818a01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Total Revenue $3.1bn; +9% pro rata FY 2021",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83af6839-4663-4388-9697-8a2621bcef52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.22,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Rare Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9eaf94ce-0399-461c-9ee0-bde703225a05",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "90eb54b5-71de-4729-abfb-edec5a5c3f0a",
      "evidence": "chart/bar-stacked: Rare Disease performance by product (Soliris, Ultomiris, Strensiq, Kanuma, Andexxa) for Q4 2020, Q4 2021, FY 2020, FY 2021",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 26,
      "beatId": "aad1cb9b-557b-4e95-ba5a-dc0050f283ae",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The closing remarks and Q&A session prompt action from the audience.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 26,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f69dbb94-83a9-490b-bc96-5831ed386c14",
      "evidence": "The presentation implies that not investing in the pipeline would mean missing out on growth opportunities.",
      "position": 1,
      "objective": "What are the consequences of not investing in AstraZeneca's pipeline?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}